Adaptimmune's enhanced T-cell therapy gets FDA breakthrough status for synovial sarcoma
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for British biopharmaceutical firm Adaptimmune Therapeutics' affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma.
ConclusionRe-staging chest CT at the time of first LR of STS identified a prevalence of 23.9% pulmonary metastases, which supports the need for chest CT at the time of LR in line with the UK guidelines for the management of bone and soft tissue sarcoma.Key Points• Pulmonary metastases were diagnosed in 1.3% of soft tissue sarcomas at presentation.• Pulmonary metastases were identified in ~ 24% of patients at first local recurrence of soft tissue sarcoma, most commonly with pleomorphic sarcoma and Trojani grade tumours.• No patient with a low-grade recurrence had pulmonary metastases.
A patient affected by a voluminous synovial sarcoma of mediastinum received radical surgery, resulting in injury of both phrenic nerves. Because of the cancer location, reconstruction of the left phrenic nerve was not possible, so to prevent the patient's ventilator dependence, the right phrenic nerve was reconstructed via an autograft from the residual proximal stump of the contralateral one. In 3 months, the right hemidiaphragm function showed a full recovery, documented by ultrasonographic and radiographic assessment of diaphragmatic excursion, and the patient was weaned from mechanical ventilation. When a nerve autogra...
Conclusion: Due to the limited number of reported cases in the literature, it is difficult to predict the outcomes of spinal SS. Further, different treatment modalities have been used to treat spinal SS. However, most of the reported cases had poor outcomes. Therefore, prospective multi-center studies are needed to further investigate the treatment strategies and outcomes for patients with spinal SS. PMID: 33024595 [PubMed]
ABSTRACTPurpose of ReviewAside from a characteristicSS18 –SSX translocation identified in almost all cases, no genetic anomalies have been reliably isolated yet to drive the pathogenesis of synovial sarcoma. In the following review, we explore the structural units of wild-type SS18 and SSX, particularly as they relate to the transcriptional alterations and cellular pathway changes imposed by SS18 –SSX.Recent FindingsNative SS18 and SSX contribute recognizable domains to the SS18 –SSX chimeric proteins, which inflict transcriptional and epigenetic changes through selective protein interactions involving th...
We report a synovial sarcoma of the tongue in a 14-year-old female patient with unusual histology.
CONCLUSION: Hand STSs are aggressive tumors with a high metastatic potential. Even with adequate oncologic treatment, long-term clinical follow-up (10 years) in these tumors is advised. The treating surgical oncologist should not be deceived by their smaller size. PMID: 32932303 [PubMed - as supplied by publisher]
Publication date: November 2020Source: Urology Case Reports, Volume 33Author(s): Premkumar Krishnappa
Date: Thursday, 09 24, 2020; Speaker: Dinah Singer, Ph.D., Deputy Director for Scientific Strategy and Development, National Cancer Institute; Cigall Kadoch, Ph.D., Associate Professor of Pediatric Oncology, Dana-Farber Cancer Institute; https://events.cancer.gov/cm/seminarseries
Synovial sarcoma (SS) is a highly aggressive soft tissue tumor with high risk of local recurrence and metastasis. However, the mechanisms underlying SS metastasis are still largely unclear. The purpose of this study is to screen metastasis-associated biomarkers in SS by integrated bioinformatics analysis. Two mRNA datasets (GSE40018 and GSE40021) were selected to analyze the differentially expressed genes (DEGs). Using the Database for Annotation, Visualization and Integrated Discovery (DAVID) and gene set enrichment analysis (GSEA), functional and pathway enrichment analyses were performed for DEGs. Then, the protein-prot...
To explore the value of radiological and clinicopathological features in the diagnosis of sinonasal synovial sarcomas (SS).